UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV

Vaccine

Volumn 30, Issue 21, 2012, Pages 3188-3195

  Jones, Bart G ^a   Sealy, Robert E ^a   Zhan, Xiaoyan ^a,d   Freiden, Pamela J ^a   Surman, Sherri L ^a   Blanchard, James L ^b   Hurwitz, Julia L ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Envelope cocktail; HIV 1 vaccine; Non human primate; Pathogenic SHIV; Ultra violet inactived vaccinia virus

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MULTIENVELOPE DNA VACCINIA VIRUS PROTEIN; PSORALEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG SAFETY; DRUG SCREENING; IMMUNE RESPONSE; MACACA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; SURVIVAL RATE; ULTRAVIOLET RADIATION; VACCINATION; VACCINIA VIRUS; VIRUS INACTIVATION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

AIDS VACCINES; ANIMALS; CD4 LYMPHOCYTE COUNT; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HIV-1; MACACA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SURVIVAL ANALYSIS; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL LOAD;

EID: 84859504575     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.001     Document Type: Article

References (36)

1. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003, 171(November (10)):4969-4973.
2. Garde V., Harper D., Fairchok M.P. Tertiary contact vaccinia in a breastfeeding infant. JAMA 2004, 291(February (6)):725-727.
3. Cono J., Casey C.G., Bell D.M. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 2003, 52(February (RR-4)):1-28.
4. Arness M.K., Eckart R.E., Love S.S., Atwood J.E., Wells T.S., Engler R.J., et al. Myopericarditis following smallpox vaccination. Am J Epidemiol 2004, 160(October (7)):642-651.
5. Slobod K.S., Lockey T.D., Howlett N., Srinivas R.V., Rencher S.D., Freiden P.J., et al. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis 2004, 23(February (2)):106-110.
6. Ramirez J.C., Gherardi M.M., Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 2000, 74(January (2)):923-933.
7. Allen T.M., Vogel T.U., Fuller D.H., Mothe B.R., Steffen S., Boyson J.E., et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 2000, 164(May (9)):4968-4978.
8. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H., et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004, 428(March (6979)):182-185.
9. Lin L., Hanson C.V., Alter H.J., Jauvin V., Bernard K.A., Murthy K.K., et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005, 45(April (4)):580-590.
10. Pamphilon D. Viral inactivation of fresh frozen plasma. Br J Haematol 2000, 109(June (4)):680-693.
11. Subklewe M., Chahroudi A., Schmaljohn A., Kurilla M.G., Bhardwaj N., Steinman R.M. Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus. Blood 1999, 94(August (4)):1372-1381.
12. Brown S.A., Surman S.L., Sealy R., Jones B.G., Slobod K.S., Branum K., et al. Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials. Viruses 2010, 2(February (2)):435-467.
13. Richmond J.F.L., Mustafa F., Lu S., Santoro J.C., Weng J., O'Connell M., et al. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology 1997, 230(April (2)):265-274.
14. Caver T.E., Lockey T.D., Srinivas R.V., Webster R.G., Hurwitz J.L. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine 1999, 17(March (11-12)):1567-1572.
15. Sealy R., Slobod K.S., Flynn P., Branum K., Surman S., Jones B., et al. Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine. Int Rev Immunol 2009, 28(1):49-68.
16. Zhan X., Martin L.N., Slobod K.S., Coleclough C., Lockey T.D., Brown S.A., et al. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 2005, 23(November (46-47)):5306-5320.
17. Stambas J., Brown S.A., Gutierrez A., Sealy R., Yue W., Jones B., et al. Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine 2005, 23(March (19)):2454-2464.
18. Hurwitz J.L., Zhan X., Brown S.A., Bonsignori M., Stambas J., Lockey T.D., et al. HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail. Front Biosci 2008, 13(January (1)):609-620.
19. Ryan K.W., Owens R.J., Hurwitz J.L. Preparation and use of vaccinia virus vectors for HIV protein expression and immunization. Immunology Methods Manual 1997, 1995-2015. Academic Press, London, England. 1st ed. I. Lefkovits (Ed.).
20. Smith G.L., Murphy B.R., Moss B. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci USA 1983, 80(December (23)):7155-7159.
21. Smith G.L., Mackett M., Moss B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 1983, 302(April (5908)):490-495.
22. Reimann K.A., Li J.T., Veazey R., Halloran M., Park I.W., Karlsson G.B., et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996, 70(October (10)):6922-6928.
23. Ulmer J.B., DeWitt C.M., Chastain M., Friedman A., Donnelly J.J., McClements W.L., et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 1999, 18(August (1-2)):18-28.
24. Lin L., Cook D.N., Wiesehahn G.P., Alfonso R., Behrman B., Cimino G.D., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997, 37(April (4)):423-435.
25. Cayabyab M., Karlsson G.B., Etemad-Moghadam B.A., Hofmann W., Steenbeke T., Halloran M., et al. Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2). J Virol 1999, 73(February (2)):976-984.
26. Mallery D.L., McEwan W.A., Bidgood S.R., Towers G.J., Johnson C.M., James L.C. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci USA 2010, 107(November (46)):19985-19990.
27. Zhan X., Slobod K.S., Surman S., Brown S.A., Coleclough C., Hurwitz J.L. Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells. Vaccine 2004, 22(March (9-10)):1206-1213.
28. Zhan X., Slobod K.S., Surman S., Brown S.A., Lockey T.D., Coleclough C., et al. Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein. J Virol 2003, 77(April (7)):4231-4236.
29. Brown S.A., Slobod K.S., Surman S., Zirkel A., Zhan X., Hurwitz J.L. Individual HIV type 1 envelope-specific T cell responses and epitopes do not segregate by virus subtype. Aids Res Hum Retroviruses 2006, 22(February (2)):188-194.
30. Surman S., Lockey T.D., Slobod K.S., Jones B., Riberdy J.M., White S.W., et al. Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc Natl Acad Sci USA 2001, 98(April (8)):4587-4592.
31. Brown S.A., Hurwitz J.L., Zirkel A., Surman S., Takimoto T., Alymova I., et al. A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein. J Virol 2007, 81(November (22)):12535-12542.
32. Surman S.L., Brown S.A., Jones B.G., Woodland D.L., Hurwitz J.L. Clearance of HIV type 1 envelope recombinant sendai virus depends on CD4(+) T cells and interferon-gamma but not B cells, CD8(+) T cells, or perforin. Aids Res Hum Retroviruses 2010, 26(July (7)):783-793.
33. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308(June (5730)):1906-1908.
34. Sealy R., Chaka W., Surman S., Brown S.A., Cresswell P., Hurwitz J.L. Target peptide sequence within infectious human immunodeficiency virus type 1 does not ensure envelope-specific T-helper cell reactivation: influences of cysteine protease and gamma interferon-induced thiol reductase activities. Clin Vaccine Immunol 2008, 15(April (4)):713-719.
35. Paradiso P.R. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis 2011, 52(May (10)):1241-1247.
36. Hurwitz J.L., Slobod K.S., Lockey T.D., Wang S., Chou T.H., Lu S. Application of the polyvalent approach to HIV-1 vaccine development. Curr Drug Targets Infect Disord 2005, 5(June (2)):143-156.